Endocyclodestruction with ophthalmologic laser microendoscope
Estrada M D, Sampietro-Colom L
Record ID 31996008523
Catalan, English, Spanish
To provide an overview of the current state of knowledge regarding the efficacy, safety and effectiveness of endocyclodestruction with ophthalmologic laser microendoscope (ECD-LM).
Authors' results and conclusions: 1. No study has been found analysing EDC-ML under ideal design conditions. Therefore, no conclusion can be made on the efficacy of this technology as regards the decrease in the IOP, which is the object of using this treatment. 2. All the studies identified on ECD-ML regarding safety (complications) and effectiveness (clinical benefits obtained under usual clinical conditions) are observational studies which are classified as low quality studies by the CAHTA document 'Levels of quality of the scientific evidence'. 3. A decrease in the IOP is achieved in all types of glaucoma, with mean values for IOP within the normal range of values (15-29 mmHg). The absolute value of the decrease varies according to the different types of glaucoma. Of all those, the best results have been found in neovascular glaucoma 4. A postsurgical decrease is observed in all patients, both in the number of topic hypotensive drugs and in the percentage of patients treated with systemic hypotensive drugs. Neovascular glaucoma has been found to have the greatest decrease in the mean of prescribed topic hypotensive drugs, and pseudofaquic eye glaucoma has been found to have the greatest decrease in the percentage of patients treated with systemic carbonic anhydrase inhibitors 5. In the analysed studies variable percentages of re-interventions are observed according to the type of glaucoma treated. As regards the safety of ECD-LM, it has to be mentioned that for about 10% of the patients with pseudofaquic eye glaucoma, open angle glaucoma and cataract glaucoma there was a progressive loss of sight 1 year after ECD-ML. However, this complication might be the result of the natural evolution of glaucoma, and not the result of ECD-LM itself.
Authors' recommendations: Although the first results of the application of ECD-ML suggest a therapeutic effect under an acceptable safety profile, this technology is at present in the first stages of clinical application. For this reason it should not be offered as an universal option in general health practice.
Project Status: Completed
Year Published: 1996
English language abstract: An English language summary is available
Publication Type: Not Assigned
Organisation Name: Agencia de Qualitat i Avaluacio Sanitries de Catalunya
Contact Address: Antoni Parada, CAHTA, Roc Boronat, 81-95 (2nd floor), 08005 Barcelona, Spain, Tel. +34 935 513 928, Fax: +34 935 517 510
Contact Name: firstname.lastname@example.org / email@example.com
Contact Email: firstname.lastname@example.org / email@example.com
Copyright: Catalan Agency for Health Technology Assessment and Research
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.